<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03948477</url>
  </required_header>
  <id_info>
    <org_study_id>CTNZ-2017-17</org_study_id>
    <nct_id>NCT03948477</nct_id>
  </id_info>
  <brief_title>Pantoprazole Prophylaxis Against Delayed CINV for Patients Receiving Breast Cancer Chemotherapy</brief_title>
  <acronym>PantoCIN</acronym>
  <official_title>Phase II, Randomised, Double-blinded, Placebo Controlled, Crossover Trial to Assess Pantoprazole's Effectiveness as Prophylaxis Against Delayed CINV in Patients Receiving Adjuvant or Neoadjuvant Breast Cancer Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Auckland, New Zealand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Auckland, New Zealand</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study explores whether a commonly used medication called Pantoprazole can help prevent
      delayed nausea and vomiting from chemotherapy for early breast cancer.

      Delayed nausea, and occasionally vomiting, can occur after breast cancer chemotherapy,
      affecting quality of life. A potential cause of these delayed side effects is that the
      chemotherapy may cause stomach irritation. Pantoprazole is commonly used to treat stomach
      irritation by reducing stomach acid, which may in turn improve nausea and/or vomiting.

      Patients undergoing breast cancer chemotherapy before or after primary surgery will be
      invited to participate in the study. They will be asked how much nausea or vomiting they have
      with and without Pantoprazole from Day 2 until 5 after they receive chemotherapy. All
      participants will still receive all of the usual anti-sickness medications, which are very
      effective in preventing sickness in the first 24 hours after treatment, but not for delayed
      symptoms.

      Information from the study may lead to a change in practice with patients using Pantoprazole
      to reduce the risks of delayed nausea and vomiting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Breast Cancer is the most common cancer type in women in New Zealand and has the second
      highest mortality (Ministry of Health NZ) Many women with early breast cancer still receive
      chemotherapy, before or after surgery and delayed nausea is a particular challenge. Ensuring
      tolerable therapy is critical to improving outcomes, by enabling patients to complete optimal
      anti-cancer therapy and to improve quality of life during therapy. Despite recent advances in
      antiemetic regimens, recent trials showed that rates of delayed Chemotherapy-Induced Nausea
      and Vomiting (CINV) are is in excess of 50%, with significant impacts on quality of life
      during treatment. This suggests that different mechanisms than those targeted by centrally
      acting anti-emetics account for such symptoms. There is strong evidence that chemotherapy
      regimens can result in gastrointestinal mucosal injury and dyspepsia. A number of studies
      have shown chemotherapy-induced dyspepsia can be relieved by a proton pump inhibitor, but
      none have reported their use as prophylaxis for delayed CINV, which may be a linked symptom.
      Proton pump inhibitors are widely used in the treatment of non-malignant dyspeptic conditions
      and are the most potent medications at reducing gastric acid secretions. They are considered
      safe in short-term use and are commonly used in clinical practice in cancer patients as well
      as the wider population. The pharmacokinetics Pantoprazole make it the ideal PPI for this
      study. The experience of New Zealand Medical Oncologists is that delayed nausea is often
      completely resolved by the delayed use of a PPI when symptoms occur. In this study we hope to
      see a 30% difference in the rates of delayed nausea by using a drug which is readily
      available and of very low cost. This will be the first time it has been used as preventive
      therapy in this setting. If this benefit occurs, it would significantly improve the treatment
      journey and may improve compliance to anti-cancer therapies.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 14, 2019</start_date>
  <completion_date type="Anticipated">July 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 14, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Double-blinded, randomised, crossover trial, phase II, stratified by the chemotherapy regimen</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Double-blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Reduce the incidence of delayed CINV in patients receiving adjuvant or neoadjuvant breast cancer chemotherapy</measure>
    <time_frame>Measured on day 5, after chemotherapy</time_frame>
    <description>To determine whether Pantoprazole can reduce the incidence of delayed CINV in patients receiving adjuvant or neoadjuvant breast cancer chemotherapy (as measured on day 5 using the MASCC Antiemesis Tool (MAT) to assess nausea over days 2-5 of each chemotherapy cycle) as compared to placebo. Specifically, the primary endpoint will be the complete absence of both nausea and vomiting during days 2-5.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nausea MAT scores</measure>
    <time_frame>Days 2-5 following chemotherapy for cycle 1 and 2 (each cycle is either 14 or 21 days)</time_frame>
    <description>Whether Pantoprazole improves nausea MAT scores over days 2-5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vomiting MAT scores</measure>
    <time_frame>Days 2-5 following chemotherapy for cycle 1 and 2 (each cycle is either 14 or 21 days)</time_frame>
    <description>Whether Pantoprazole reduces the number of episodes of vomiting (MAT) over days 2-5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heartburn improvement</measure>
    <time_frame>Days 2-5 following chemotherapy for cycle 1 and 2 (each cycle is either 14 or 21 days)</time_frame>
    <description>Whether Pantoprazole improves heartburn score (measured using the FSSG for reflux and/or dyspepsia) as self-reported on day 5 regarding days 2-5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heartburn and Nausea scores</measure>
    <time_frame>Days 2-5 following chemotherapy for cycle 1 and 2 (each cycle is either 14 or 21 days), using a regression model, with allowance for a possible non-linear relationship.</time_frame>
    <description>Whether FSSG scores (heartburn) are associated with the MAT nausea scores reported by the patient over days 2-5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of breakthrough medications</measure>
    <time_frame>Days 2-5 following chemotherapy for cycle 1 and 2 (each cycle is either 14 or 21 days)</time_frame>
    <description>Whether Pantoprazole lowers the requirement for breakthrough medications (as self-recorded by the patients on days 2-5).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient preference</measure>
    <time_frame>end of chemotherapy cycle 2 (cycle 2 is either 14 or 21 days)</time_frame>
    <description>Whether Pantoprazole is preferred by patients over Placebo (by using a patient preference survey at the end of cycle 2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>From date of consent to 28 days after the last study treatment</time_frame>
    <description>To assess whether adverse events (including hypomagnesemia, diarrhoea, abdominal pain and headache as defined by CT CAE version 4.03) are more common on Pantoprazole than on Placebo.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Effect of chemotherapy regimen impacts use of Pantoprazole in terms of delayed CINV</measure>
    <time_frame>Measured on day 5, after chemotherapy</time_frame>
    <description>Whether the chosen chemotherapy regimen (FEC vs AC vs TC) has an impact on the benefits of Pantoprazole in terms of delayed CINV, (as measured on day 5 using the MASCC Antiemesis Tool (MAT) to assess nausea over days 2-5 of each chemotherapy cycle) as compared to placebo.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cycle effect</measure>
    <time_frame>Cycle 1 to end of cycle 2 (each cycle is either 14 or 21 days)</time_frame>
    <description>To determine whether there is a cycle effect with respect to the incidence of delayed CINV as measured with the MAT (as measured on day 5 using the MASCC Antiemesis Tool (MAT) to assess nausea over days 2-5 of each chemotherapy cycle).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Oncology</condition>
  <condition>Breast Cancer</condition>
  <condition>Chemotherapy-induced Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>Pantoprazole/Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will take one 40 mg capsule of Pantoprazole daily for 5 days at the beginning of cycle 1 then they will take one capsule of matched Placebo daily for 5 days at the beginning of cycle 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/Pantoprazole</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will take one capsule of matched Placebo daily for 5 days at the beginning of cycle 1 then they will take one 40 mg capsule of Pantoprazole daily for 5 days at the beginning of cycle 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pantoprazole 40mg</intervention_name>
    <description>Proton pump inhibitor, drug action is to irreversibly block the hydrogen-potassium adenosine triphosphatase enzyme system (the 'proton pump') of the gastric parietal cell. This reduces basal and stimulated gastric acid secretion therefore raising gastric pH.</description>
    <arm_group_label>Pantoprazole/Placebo</arm_group_label>
    <arm_group_label>Placebo/Pantoprazole</arm_group_label>
    <other_name>Apo-Pantoprazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matched placebo</description>
    <arm_group_label>Pantoprazole/Placebo</arm_group_label>
    <arm_group_label>Placebo/Pantoprazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men or women who are being considered for adjuvant or neoadjuvant chemotherapy with
             either FEC or AC or TC chemotherapy and have been deemed by their treating Oncologist
             as being fit for treatment. The scheduled length of each chemotherapy cycle must be
             14-21 days.

          2. Age â‰¥18 years.

          3. Willing to comply with all study requirements, including treatment (being able to
             swallow tablets), timing and nature of required assessments.

          4. All patients must be able to speak and read in English to ensure consent is informed
             and documentation of patient-reported outcome measures can be adhered to.

          5. Signed, written informed consent.

             -

        Exclusion Criteria:

          1. Patients who are receiving therapy to reduce gastric acid (including proton pump
             Inhibitors (e.g. Omeprazole, Pantoprazole, Lansoprazole, Esomeprazole or Histamine
             type-2 receptor antagonists e.g. Ranitidine)) at the time of enrolment will be
             excluded from the trial.

          2. Patients with pre-existing hypomagnesemia as defined by the reference range at the
             investigating sites laboratory.

          3. Patients with a history of cardiac arrhythmias including atrial fibrillation or
             paroxysmal tachycardias.

          4. Patients with known metastatic disease.

          5. The presence of any serious medical or psychiatric conditions, which might limit the
             ability of the patient to comply with follow up.

          6. The presence of any psychological, familial, sociological or geographical condition
             potentially hampering compliance with the study protocol and follow up schedule,
             including alcohol dependence or drug abuse.

          7. Pregnancy, lactation or inadequate contraception. Women must be postmenopausal,
             infertile, or use a reliable means of contraception. Women of childbearing potential
             must have a negative pregnancy test done within 7 days prior to registration.

             -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ricard Isaacs, MBChB FRACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Midcentral Regional Cancer Centre Services</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Navin Wewala, MBChB FRACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Midcentral Regional Cancer Centre Services</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Louise Clement, MA</last_name>
    <phone>+64 (0)99234626</phone>
    <email>louise.clement@auckland.ac.nz</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sarah Benge, PhD</last_name>
    <phone>+64 (0)9 923 3585</phone>
    <email>s.benge@auckland.ac.nz</email>
  </overall_contact_backup>
  <link>
    <url>http://cancertrialsnz.blogs.auckland.ac.nz/pantocin</url>
    <description>Cancer Trials New Zealand website study record</description>
  </link>
  <link>
    <url>https://www.breastcancerfoundation.org.nz/clinical-trials/clinical-trial/pantocin-</url>
    <description>Breast Cancer Foundation website study record (Co-funder)</description>
  </link>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>March 28, 2019</study_first_submitted>
  <study_first_submitted_qc>May 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2019</study_first_posted>
  <last_update_submitted>May 9, 2019</last_update_submitted>
  <last_update_submitted_qc>May 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Auckland, New Zealand</investigator_affiliation>
    <investigator_full_name>Dr Richard Isaacs</investigator_full_name>
    <investigator_title>Medical Oncologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pantoprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

